Jennifer G. Baker

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer

John D. Norris, Stephanie J. Ellison, Jennifer G. Baker et al. · Journal of Clinical Investigation · 2017 · 58 citations · Full text

The Dysregulated Pharmacology of Clinically Relevant <i>ESR1</i> Mutants is Normalized by Ligand-activated WT Receptor

Kaitlyn J. Andreano, Jennifer G. Baker, Sunghee Park et al. · Molecular Cancer Therapeutics · 2020 · 50 citations · Full text

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

Kaitlyn J. Andreano, Suzanne E. Wardell, Jennifer G. Baker et al. · Breast Cancer Research and Treatment · 2020 · 46 citations · Full text

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer

Julie A. Pollock, Suzanne E. Wardell, A.A. Parent et al. · Nature Chemical Biology · 2016 · 21 citations · Full text

Urology, Medicine, Hormonal Receptor +4

Abstract 5641: Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer

Suzanne E. Wardell, Alexander P. Yllanes, Jennifer G. Baker et al. · Cancer Research · 2017 · 16 citations

Breast Oncology, Relevant Tamoxifen, Chemoprevention Strategy +20